These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 25303321)
1. Economical impact associated with a biological therapy prioritization protocol in patients with rheumatoid arthritis in the Hospital of Sagunto. Borrás-Blasco J; Casterá MD; Cortes X; Rosique-Robles JD; Abad FJ Expert Opin Biol Ther; 2014 Nov; 14(11):1561-7. PubMed ID: 25303321 [TBL] [Abstract][Full Text] [Related]
2. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803 [TBL] [Abstract][Full Text] [Related]
4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis. Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519 [TBL] [Abstract][Full Text] [Related]
5. Economic impact of rheumatoid arthritis (RA) biotherapies in France. Maravic M Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751 [TBL] [Abstract][Full Text] [Related]
6. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008 [TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. Carter CT; Changolkar AK; Scott McKenzie R J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788 [TBL] [Abstract][Full Text] [Related]
8. [Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)]. Rubio-Terrés C; Ordovás Baines JP; Pla Poblador R; Martínez Nieto C; Sánchez Garre MJ; Rosado Souvirón MA; Sierra Muñoz A; Sánchez Mateo M; Farm Hosp; 2007; 31(2):78-92. PubMed ID: 17590116 [TBL] [Abstract][Full Text] [Related]
9. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
10. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Nuijten MJ; Engelfriet P; Duijn K; Bruijn G; Wierz D; Koopmanschap M Pharmacoeconomics; 2001; 19(10):1051-64. PubMed ID: 11735673 [TBL] [Abstract][Full Text] [Related]
11. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424 [TBL] [Abstract][Full Text] [Related]
12. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice. Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583 [TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data. Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816 [TBL] [Abstract][Full Text] [Related]
14. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Tang B; Rahman M; Waters HC; Callegari P Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998 [TBL] [Abstract][Full Text] [Related]
15. [Analisis of the budget impact of adalimumab and etanercept in rheumatoid arthritis and spondyloarthropathies]. González Álvarez A; Gómez Barrera M; Borrás Blasco J; Giner Serret EJ Farm Hosp; 2013; 37(3):192-7. PubMed ID: 23789797 [TBL] [Abstract][Full Text] [Related]
16. [Adalimumab versus etanercept in the treatment of active rheumatoid arthritis: cost-effectiveness analysis]. González Álvarez A; Gómez Barrera M; Borrás Blasco J; Giner Serrer EJ Farm Hosp; 2013; 37(4):286-94. PubMed ID: 24010689 [TBL] [Abstract][Full Text] [Related]
17. Minimum effective dosages of anti-TNF in rheumatoid arthritis: a cross-sectional study. de la Torre I; Valor L; Nieto JC; Montoro M; Carreño L Reumatol Clin; 2014; 10(2):101-4. PubMed ID: 24280444 [TBL] [Abstract][Full Text] [Related]
18. Dealing with the high cost of biological therapies: developing and implementing a biological therapy prioritization protocol for ankylosing spondylitis patients in a tertiary hospital. Borrás-Blasco J; Casterá E; Cortes X; Martín-Alonso J; Rosique-Robles JD; Abad FJ Int J Clin Pharmacol Ther; 2015 Dec; 53(12):997-1004. PubMed ID: 26413730 [TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Spalding JR; Hay J Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076 [TBL] [Abstract][Full Text] [Related]